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INTRODUCTION
Long-chain (>14 carbon atoms) polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA, C20:5 -3) and arachidonic acid (AA, C20:4 -6) play crucial roles in normal human physiology and the pathophysiology of several major diseases, including cancer and neurodegenerative diseases [1, 2] . Dietary intake, or administration of purified supplement formulations, of the -3 PUFAs EPA and docosahexaenoic acid (DHA, C22:6 -3) is increasingly recognised to have likely therapeutic benefit for a range of conditions such as cardiovascular disease [3, 4] , neurological disorders [5, 6] and cancer [7, 8] .
Lipophilic PUFAs exist predominantly in the plasma membrane following dietary and supplement intake. This property means that measurements of relative and absolute PUFA content of cells and tissues can potentially be used as a disease risk biomarker in observational studies or as a predictive biomarker in intervention studies. In the context of intervention trials, specific PUFA levels in erythrocyte membranes or the plasma phospholipid fraction can be used as a measure of compliance, baseline dietary -3 PUFA intake and individual variability in PUFA content [9] .
Therefore, there exists a requirement for a robust, reproducible method of PUFA measurement easily applicable to pre-clinical and clinical use. Traditionally, gas chromatography-mass spectrometry (GC-MS) has been employed for relative quantification of FA content in the lipid phase of biological samples in vitro and in vivo [10] . However, there are limitations to GC-MS quantification of PUFAs. For example, electron ionisation
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A c c e p t e d M a n u s c r i p t typically involves high energies, causing structural rearrangement of lipids that produce overlapping spectra for different PUFAs, which can make data interpretation problematic [10] , though using a suitable column, many of these can be separated chromatographically. Moreover, very high temperatures are required, which is not always suitable for analysis of PUFAs due to sensitivity to thermal degradation [11] . This can be problematic, however these high temperatures are not necessary for LC/MS/MS and therefore thermal degradation is unlikely to occur.
Liquid chromatography (LC) in combination with electrospray ionization triple quadrupole tandem mass spectrometry (ESI-MS/MS) is now widely available in many laboratories. This has led to the development of several ESI-MS/MS methods with or without derivatisation steps [12] . A number of derivatisation agents, which are simple to incorporate during sample preparation and increase sensitivity of LC-ESI-MS/MS for PUFA analysis, are now available. Benzofuran and diazoalkane derivatisation has been reported to lower the limit of detection by enhancing fragmentation patterns during MS, thus increasing sensitivity [13] [14] [15] . However, no LC-ESI-MS/MS method has been compared directly to established GC-MS methodology for multiple FA measurement in biological samples. Herein, we describe a new LC-ESI-MS/MS method for measurement of fatty acids (FAs) using widely available equipment and amenable to high-throughput analysis. We compare the novel LC-ESI-MS/MS method to a well-established GC-MS protocol [16, 17] for FA analysis in biological samples.
We also confirmed applicability of the LC-ESI-MS/MS method to animal and human samples in the context of EPA supplementation experiments. Finally, we highlight the use of the LC-ESI-MS/MS method to compare relative changes in free (unesterified) and total (free + esterified) cellular PUFA content after exogenous EPA exposure.
METHODS

Reagents.
EPA free fatty acid (FFA) was provided by SLA Pharma AG (Watford, UK). Use of EPA-FFA in in vitro experiments has been described previously [17] . Acetonitrile, methanol, 2-propanol, water and chloroform used Page 5 of 32 A c c e p t e d M a n u s c r i p t for fatty acid extraction were purchased from Sigma Aldrich (St. Louis, MO, USA) and were UHPLC-MS grade.
Deionised purified water was generated using an Elga Maxima and Elga Purelab Option purifying system (18.2 MΩ-cm) (Veolia Water Technologies UK, High Wycombe). 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide HCl (EDC), 4-(Dimethylamino) pyridine (DMAP), 4-[2-(N,N-Dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (DAABD-AE) and fatty acid standards; eicosapentaenoic acid (EPA C20:5 -3), docosapentaenoic acid (DPA, C22:5 -3), docosahexaenoic acid (DHA C22:6 -3), alpha-linolenic acid (LNA C18:3 -3), arachidonic acid (AA C20:4 -6), linoleic acid (LA, C18:2 -6), stearic acid (SA, C18:0), oleic acid (OA C18:1 -9) and palmitic acid (PA, C16:0), were also purchased from Sigma Aldrich. Internal standard, deuterated alpha-linolenic acid (LNA-d 14 ) , was purchased from Cayman Chemical (Ann Arbor, Michigan, USA).
In vitro studies.
MC38 mouse colorectal cancer (CRC) cells were a gift from Professor Daniel Beauchamp (Vanderbilt Institute, USA). HCA-7 human CRC cells were obtained from the American Type Culture Collection (UK). Cells were cultured in RPMI 1640 medium containing Glutamax supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS) (all Thermofisher Scientific, UK), at 37C in a humidified atmosphere containing 5% CO 2 .
Cells were routinely sub-cultured using 0.25% (w/v) trypsin (Thermofisher Scientific, UK). Viable cells were counted using a haemocytometer in the presence of 0.04% (v/v) trypan blue (Sigma-Aldrich, UK).
For each cell line, an equal number of viable cells were seeded in tissue culture flasks and left to reach 60-70% confluence. Cells were then treated with either ethanol carrier (0.6% v/v) or EPA-FFA and incubated for 24 hr.
Cells were then washed twice with sterile PBS (Thermofisher Scientific, UK) and harvested by trypsinisation.
The cell suspensions obtained were counted and centrifuged at 500 g for 5 min at room temperature. The cell pellets were then stored at -80 o C until analysis.
In vivo studies.
C57Bl/6 mice were housed in a specific pathogen-free environment. All experiments were undertaken with UK Home Office approval. Eight week-old female C57Bl/6 mice were administered one of two iso-caloric test diets 
Human studies.
We used data from 8 patients who took part in the EPA for Metastasis Trial (EMT, [16] ), in which blood samples for plasma and erythrocyte extraction were obtained before and after intervention (EPA treatment median duration of 44 days). The full data set from erythrocyte membrane PUFA content analysis, of 88 patients (including the 8 samples included here) has previously been published [9] .
GC-MS: extraction and analysis.
The relative FA content of MC38 cells exposed to EPA-FFA was measured by GC-MS, as previously described [18, 19] . In brief samples, into which internal standard was added (Heneicosanoic acid, 2.5 µg/sample), were homogenized in 0. Analytes were derivatized into free fatty acids (FA) by a base-catalyzed reaction (2 ml of KOH 0.5M in Methanol, 80°C, 10 min) and then esterified to form fatty acid methyl esters (FAMEs) in an acid-catalyzed reaction using boron trifluoride in methanol, (1 ml BF 3 , 80°C, 10 min) [20] FAMES were then extracted twice with Hexane (3+2ml) and then taken to dryness until used.
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The FAMES mixture was then injected onto a gas chromatograph for separation (Agilent HP5890, equipped with 
LC/MS: Extraction of FAs from biological samples.
FAs were extracted from samples using an isopropanol/chloroform method (figure 1) adapted from the protocol first published by Rose et al. [22] . Tissue homogenates or washed erythrocytes (50 l) were mixed with 50 l of distilled water, containing internal standard (LNA-d 14 ) at 2 g/ml, and allowed to stand for 15 min. For blanks and controls, samples were substituted with PBS or a mix of FA standards (2 g/ml). Isopropanol was added slowly to a volume of 650 l with mixing, and following incubation for 1 hr at room temperature, 350 l of chloroform was added. After a further 1 hr incubation, samples were centrifuged at 10,000 g for 5 min. The supernatant was then evaporated to dryness in a rotary evaporator (EZ-2 plus rotary evaporator, Genevac Ltd, Suffolk, UK), and those extracts destined to undergo hydrolysis were reconstituted in 500 l acetonitrile. Saponification by acid hydrolysis was performed with the addition of 50 l 5M HCl followed by incubation at 80°C for 1 hr. 50 l of 5M NaOH was then added to neutralise, before the addition of 350 l chloroform. The samples were left to stand for 5min, before isolating the top 800 l for evaporation. Extracted FAs from hydrolysed and non-hydrolysed samples were reconstituted in 50 l methanol prior to derivatisation.
LC/MS: Derivatisation of extracted FAs.
50 l of EDC, 50 l of DMAP and 50 l of the derivatising agent DAABD-AE (all 10mg/ml in methanol), were mixed with each 50 l sample of FA extract. The mixture was then incubated for 24 hr at room temperature in amber glass HPLC vials. The resulting FA derivatives were measured by LC-ESI-MS/MS.
LC-ESI-MS/MS analysis.
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Samples were analysed using a Waters Alliance 2695 High Pressure LC separations module in combination with a Waters Micromass Quattro Ultima triple quadrupole mass spectrometer (Waters UK, Hertfordshire). Table 1 .
Results are expressed for each FA as the percentage of the total analysed FA content for that sample, calculated as the sum of the ratio of each FA peak area to the internal standard peak area (%FA).
Statistical analysis.
All statistical analyses were performed using GraphPad Prism 6. Bland-Altman curves and linear regression analysis were used to compare the two MS methodologies. The statistical significance of differences in % FA were analysed using the multiple T-test with Holm-Sidak correction ( = 0.05).
RESULTS
LC-ESI-MS/MS performance for FA measurement.
We developed a FA extraction and LC-ESI-MS/MS analysis method to quantify 9 FAs in a range of biological samples. Table 1 summarises the detection parameters for each FA. Typical MS traces are illustrated in the supplementary figure S1. The limit of detection (LOD) for the FAs was routinely below 1 ng/ml equating to an on-column injection of 2pg of FA, except for SA and PA, for which an accurate LOD could not be determined
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A c c e p t e d M a n u s c r i p t due to background contamination levels. The limit of quantification (LOQ) and linear range of quantification for each FA was also determined (table 1) . The linear range was established as 0.01-50 g/ml for EPA, DPA, LNA, AA and LA. The DHA linear range was wider, from 0.001 to 50 g/ml, whilst SA, OA and PA could only be quantified in concentrations ranging between 0.1 and 50 g/ml because of high background levels (table 1) . To assess the reproducibility and accuracy of the method, we determined intra-day and inter-day coefficient of variations (CV) for absolute concentrations of each FA (table 2) . Calibration curves were prepared daily and injected in triplicate over 3 days. There was good reproducibility and accuracy with intra-day and inter-day %CVs consistently <20% and % accuracy within 10%. The intra-and inter-day %CV data were also calculated from the FA chromatographic peak area to internal standard peak area ratio to facilitate the comparison with published GC-MS data (table 3) . The LC-ESI-MS/MS method therefore allowed us to quantify each of the 9 FAs and express the amount of FA detected either as an absolute concentration (weight/volume) or as a percentage amount relative to the total FA weight or % amount relative to the total FA peak area. The latter is the most common way of expressing relative FA amounts in biological samples by GC-MS. We therefore expressed the LC-ESI-MS/MS data as the percentage of each FA relative to the total FA peak area (%FA) in order to facilitate the comparison with GC-MS data.
Comparison of LC-ESI-MS/MS and GC-MS for the measurement of FAs in vitro.
We performed a direct comparison between GC-MS and LC-ESI-MS/MS FA measurements in biological samples. We used MC38 mouse CRC cells, which are established in our laboratory for studies of EPA anti-CRC activity, in order to compare the LC-ESI-MS/MS method on hydrolysed FA extract samples against GC-MS. figure 2 and 3) . SA measurements between the two methods showed a mean bias of 9.6 ± 2.9 points with 95% limits of agreement from -3.9 to 15.3 ( figure 3 ). OA measurements showed a mean bias of -17.5 ± 3.4 points (95% limits of agreement -24.2 to -10.8). Bias between the methods restricted to SA and OA might be explained by differences in glassware and plastic FA contamination between the laboratories [23] , which performed the LC-ESI-MS/MS (Bradford) and the GC-MS (Bologna) analyses.
Linear regression analysis for each FA revealed a statistically significant correlation between the methods for all FAs, which was weakest for SA ( figure 4 and table 1 ). Taken together, these data reveal good correlation and agreement between the LC-ESI-MS/MS method and GC-MS for measurement of PUFAs in cultured cells in the context of -3 PUFA treatment.
Measurement of omega-3 PUFA incorporation in mouse liver.
Next, we applied the LC-ESI-MS/MS method to the measurement of FA content in more complex biological samples. C57Bl/6 mice bearing MC38 mouse CRC cell tumours received EPA-containing or control diet for 4 weeks prior to sacrifice. LC-ESI-MS/MS analysis of hydrolysed lipid extracts from liver samples revealed a significant increase in the % amount of EPA, DPA and DHA, as well as a significant reduction in the relative amount of AA, LA and OA in the liver of mice fed the diet containing 5% (w/w) EPA (figure 5, p<0.05). These FA values are similar to those obtained by GC-MS measurement in a previously published EPA treatment experiment [18] . Therefore, the LC-ESI-MS/MS method can detect omega-3 PUFA changes in mouse tissue following exogenous administration of EPA.
Measurement of omega-3 PUFAs in clinical samples.
We then tested the applicability of the LC-ESI-MS/MS method for FA analysis in a clinical setting, using a subset of clinical samples from the EMT study [9, 16] . We analysed the total FA content of erythrocytes from 8 participants before and after treatment with EPA-FFA 2 g daily using the hydrolysis method, i.e. total FA ( figure   6 ). The % EPA content relative to the total FA pool was significantly increased after EPA treatment compared
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A c c e p t e d M a n u s c r i p t with baseline (2.26±0.47% compared with 0.77±0.06%). EPA was the only FA that demonstrated a statistically significant change in relative amount (p<0.05; figure 6 ). Clinical samples were also split in 5 aliquots before extraction and injected the same day to assess reproducibility in clinical samples. The intra-sample variation data calculated after multiple extraction and analysis of one sample showed excellent reproducibility with %CV values between 2.2-5.5% for each FA, with the exception of SA and PA, which were much higher due to background (calculated from ratio to internal standard, table 3). A c c e p t e d M a n u s c r i p t
Use of LC-ESI-MS/MS to distinguish changes in free
DISCUSSION
We describe an accurate and reproducible LC-ESI-MS/MS method for the analysis of FAs in cultured cells, and also animal and human samples. We found one prior study comparing LC-ESI-MS/MS method to GCcombustion-isotope ratio MS to measure [ 13 C16]-palmitate enrichment in volunteers [24] . However, this is the first direct comparison of LC-ESI-MS/MS to the 'gold-standard' GC-MS method for multiple non labelled FA relative content and it has confirmed excellent agreement for FA analysis between the methods.
Several LC-MS/MS protocols have previously been published for FA analysis [23, [25] [26] [27] , some of which use linear ion trap quadrupole tandem mass spectrometers, often reporting relatively high LOD (up to 1ug/ml, [26] )
while others have restricted methodology to EPA only [25] or EPA, DHA and AA [27] . Of note is the method of
Yung et al demonstrating an excellent LOD of 0.25 ng/ml, however this is for a urea-based analog of EPA [28] .
Here we describe the comprehensive analysis of a range of FAs (DPA, DHA, AA, EPA, SA, OA, LA, LNA, PA) using triple quadrupole mass spectrometry, systems which are widely available in most analytical laboratories although the methodology is suitable for ion trap systems also.
The use of DAABD-AE as a derivatisation agent was first developed by Tsukamoto et al. [29] , specifically for reactions with carboxylic acids and specifically for sensitive detection using ESI-MS. Use of DAABD-AE has been previously optimized [30] , resulting in a convenient derivatisation process producing a highly sensitive analytical method when used in combination with LC/MS/MS. Fatty acids are known to produce a complex fragmentation when subject to ESI. However, DAABD-AE derivatisation stabilised all the FAs analysed, producing a characteristic product ion spectrum with a consistent major fragment ion at m/z 150.5. This characteristic fragment can be explained by the dimethylaminoethylaminosulfonyl fragment within DAABD-AE [30] . Indeed a precursor ion scan for m/z 150.5 would be a good opportunity to find more potential FAs in the chromatographic run, if needed.
Separation of the 9 FAs was satisfactory using our column of choice (2.1 mm x 250 mm, 5 m particle size).
However, the methodology would be easily adaptable to UPLC using 1.7 m particles, if required. The assay is
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A c c e p t e d M a n u s c r i p t also suitable for the investigation of other disease states such as peroxisomal disorders, for example by the inclusion of other fatty acids including pristanic acid, phytanic acid. We appreciate that double bond positional isomers (e.g., -3 vs -6 species with the same m/z value) may be present together in human and animal samples and have confirmed that we can, for example, separate and hence differentiate, between -6 DPA and -3 DPA (unpublished data).
The increased LOQ and LOD (up to 100ng/ml) for PA, OA and SA was due to the small, but consistent background interference and was compensated by use of blank controls, which were subtracted from analysed samples. Background interference is a widely reported problem for FA analysis, in particular for SA and PA, resulting in a higher LOQ than for many other fatty acids [23] . This could be a substantial issue for analysis of free FA but is less so for analysis of membrane FA incorporation as the concentration of an individual FA being analysed is relatively high compared to background. It is important to take background FA presence into account using appropriate control samples.
Sensitivity is not usually a concern with the high concentrations of FA present in most biological samples.
However, the low LODs reported here would enable the development of an assay relevant for micro-sampling techniques such as finger-prick blood sampling [31]. The straightforward methodology described here is also amenable to small sample analysis. Furthermore, the protocol has now been adapted to a high throughput format allowing FA extraction in 96-well plates using 2ml Sirocco protein precipitation plates (Waters UK). A c c e p t e d M a n u s c r i p t
The method is also versatile in that it is very easy to change between the analysis of hydrolysed and nonhydrolysed FA extracts from a range of sources. We are aware of one other report in which LC-MS/MS was used to distinguish between free (unesterified) and total FAs by avoidance of a hydrolysis step but the aim was to detect unesterified EPA in the plasma following oral administration of -EPA ethyl ester rather than investigating compartmentalisation in cells [25] . One other study looked at PUFA distribution in cells comparing free and esterified fluorescent PUFAs in cells overexpressing the liver-type fatty acid-binding protein [33] . This study showed that the proportion of free, unesterified EPA in cells is greater than for other PUFAs, which is consistent with our data [33] . These data, together with our study, indicate that FAs may compartmentalise differently A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
